Literature DB >> 28528021

Multicystic peritoneal mesothelioma: A short review.

Chi-Hao Zhang1, Ji-Wei Yu1, Meng Luo2.   

Abstract

Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, predominantly affecting female patients during their reproductive years. The lesion is usually distributed diffusely in the abdomen and pelvis, but the peritoneum of the pelvic organs is the most common site. MCPM is composed of fluid-filled translucent cysts, connected by varying amounts of fibrous tissue, and lined by a layer of mesothelial cells. Because of the rarity of this disease, the pathogenesis and natural history of MCPM remain poorly understood and continuously debated. Some authors consider it to be a reactive process for its association with prior surgery or abdominal inflammation. But its high rate of local-regional recurrence, as well as its malignant potential, suggests a neoplastic etiology. Preoperative diagnosis is often very difficult. Imaging methods, such as ultrasound, computed tomography, and magnetic resonance imaging, are of little value for an accurate diagnosis of MCPM. The definitive diagnosis relies on histologic examination of target lesions combined with immunohistochemical stains. There is no consensus on the clinical management of MCPM, although surgical removal remains the first-line treatment of choice. But no standards have been reached concerning which surgical options-traditional debulking surgery or more aggressive one-should be chosen. Alternative therapeutic approaches include hand-off treatment, hormonal supplementation, laser vaporization, and sclerotherapy, and they all come with uncertain results. Moreover, the lesions show no response to adjuvant chemotherapy and radiotherapy. This article aimed to focus on those controversial problems in pathogenesis, natural history, diagnosis, and treatment strategies to help medical workers to better understand this rare disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; Estrogen; Hyperthermic intraperitoneal chemotherapy; Multicystic peritoneal mesothelioma; Progesterone

Mesh:

Substances:

Year:  2017        PMID: 28528021     DOI: 10.1016/j.currproblcancer.2017.03.002

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  7 in total

1.  Benign multicystic peritoneal mesothelioma: literature review and update.

Authors:  Momal Tara Chand; Jacob Edens; Tayson Lin; Ian Anderson; Richard Berri
Journal:  Autops Case Rep       Date:  2020-06-05

2.  Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  A Zahid; L Clarke; N Carr; K Chandrakumaran; A Tzivanakis; S Dayal; F Mohamed; T Cecil; B J Moran
Journal:  BJS Open       Date:  2021-03-05

3.  Acute presentation of multi-cystic peritoneal mesothelioma.

Authors:  Mark Redden; Andrew Riddell
Journal:  J Surg Case Rep       Date:  2022-01-22

4.  Benign multicystic peritoneal mesothelioma occurring in bilateral inguinal canals metachronously: a case report.

Authors:  Hiroyuki Oshikiri; Yohei Ozawa; On Suzuki; Masahiro Usuda; Go Miyata
Journal:  Surg Case Rep       Date:  2022-03-16

5.  Multicystic peritoneal mesothelioma treated with complete cytoreductive surgery, peritonectomy and hyperthermic intra-peritoneal chemotherapy-A case report.

Authors:  Naveen Padmanabhan; Haruaki Ishibashi; Kazurou Nishihara; Shouzou Sako; Kanji Katayama; Satoshi Wakama; Yasuyuki Kamada; Yutaka Yonemura
Journal:  Int J Surg Case Rep       Date:  2020-08-08

Review 6.  Multicystic peritoneal mesothelioma: a systematic review of the literature.

Authors:  Barbara Noiret; Florence Renaud; Guillaume Piessen; Clarisse Eveno
Journal:  Pleura Peritoneum       Date:  2019-09-25

7.  Sclerosing encapsulating peritonitis as a rare cause of intestinal obstruction after the treatment of peritoneal mesothelioma: a case report and review of the literature.

Authors:  Zhizhan Ni; Qing Chen; Chenshen Huang; Song Wang; Qi Huang
Journal:  Transl Cancer Res       Date:  2021-06       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.